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Abstract
Rationale Major depressive disorder has been associated with
low serum levels of brain-derived neurotrophic factor
(sBDNF), which is functionally involved in neuroplasticity.
Although sBDNF levels tend to normalize following psycho-
pathological improvement with antidepressant treatment, it is
unclear how closely sBDNF changes are associated with
treatment outcome.
Objectives To examine whether baseline sBDNF or early
changes in sBDNF are predictive of response to therapy.
Methods Twenty-five patients with major depressive disorder
underwent standardized treatment with duloxetine. Severity of
depression, measured by the Hamilton Depression Rating
Scale, and sBDNF were assessed at baseline, and after 1, 2,
and 6 weeks of treatment. Therapy outcome after 6 weeks was
defined as response (≥50 % reduction in baseline Hamilton
Depression Rating score) and remission (Hamilton Depres-
sion Rating score <8). The predictive values for treatment
outcome of baseline sBDNF, and early (i.e., ≤2 weeks)
changes in sBDNF and Hamilton Depression Rating score
were also assessed.
Results At baseline, sBDNF correlated with Hamilton De-
pression Rating scores. Treatment response was associated
with a higher baseline sBDNF concentration, and a greater
Hamilton Depression Rating score reduction after 1 and
2 weeks. A greater early rise in sBDNF correlated with a
decreased early Hamilton Depression Rating score reduction.
Conclusions Even though higher baseline sBDNF levels are
associated with more severe depression, they may reflect an
increased capacity to respond to treatment. In contrast, chang-
es in sBDNF over the full course of treatment are not associ-
ated with psychopathological improvement.
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Introduction
Brain-derived neurotrophic factor (BDNF) is one of a family
of neurotrophins, located in the brain and peripheral tissues,
playing an essential role in neuronal cell differentiation,
growth, and survival (Hallbook 1999). Serum and plasma
BDNF (s/pBDNF) levels are associated with functional and
efficient neuronal functioning. Lower s/pBDNF levels have
been observed in patients with major depressive disorders.
Duman and Monteggia (2006) posited that a deficit in
s/pBDNF in cases of major depressive disorders (MDD) is
associated with increased stress, psychopathology, and im-
paired neuroplasticity.
Lower concentrations of sBDNF in depression, initially
observed by Karege et al. (2005), have since been replicated
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in several other studies (see reviews by Sen et al. 2008, and
Bocchio-Chiavetto et al. 2010). Although the studies vary in
design, sample size, and BDNF analysis, the association be-
tween MDD and lower BDNF levels is quite consistent.
Despite the numerous replications of this link, the relationship
between changes in BDNF levels and treatment outcome in
patients with MDD are more inconsistent (Aydemir et al.
(2006), Brunoni et al. (2008), Gervasoni et al. (2005), Kim
et al. (2007), Shimizu et al. (2003), Yoshimura et al. (2007),
and Huang et al. (2008)). All reported correlations between
BDNF level increases and reduced depression, though meth-
odological limitations (e.g., small sample sizes, pre-post-
comparisons, use of a variety of antidepressants) preclude
generalization and still leave questions about the link between
MDD and BDNF change. Additionally, comparative studies
investigating the differential effect of specific antidepressants
on BDNF level changes during treatment indicate that the
association between such changes and treatment outcome
depends on the antidepressant employed. In a comparative
study by Hellweg et al. (2008), amitriptyline treatment was
associated with a significant increase in sBDNF concentra-
tions, but with paroxetine treatment there was a slight de-
crease. Matrisciano et al. (2009) found a rise in sBDNF after
5-weeks treatment with sertraline, though only after 6-months
treatment with venlafaxine. Finally, in a prospective study
involving 4 weeks of antidepressant treatment with
venlafaxine or mirtazapine, sBDNF levels declined with the
former but increased with the latter (Deuschle et al. 2013).
To summarize, whereas the association between severe
MDD and low s/pBDNF is well established, uncertainties
remain about relations between changes in MDD and
s/pBDNF during treatment. Given the inconsistent effects of
different antidepressants on BDNF, the question arises wheth-
er an increase of BDNF levels are at all necessary for any
therapeutic antidepressant effect. Another question is whether
an increase of BDNF levels can predict treatment outcome.
Three studies have examined this question. Haghighi et al.
(2013) found an increase in pBDNF in patients treated with
citalopram and with electroconvulsive therapy (ECT) but no
significant advantage or disadvantage in treatment outcome.
Tadić et al. (2011) reported that early non-increase in sBDNF
concentrations was linked to non-response to antidepressant
treatment. Further, they specifically tested how sensitive early
change in pBDNF was as a predictor of treatment outcome
(Dreimüller et al. 2012). Results indicated that a 100 % +
increase in pBDNF concentration over baseline after 1 week,
and a ≥20 % improvement in Hamilton Depression Rating
Scale (HDRS) score at day seven both predicted the final
response to antidepressant treatment with considerable
sensitivity.
These latter two studies suggest that early changes in
s/pBDNF levels are associated with reduction in MDD symp-
toms, and in our view this merits further investigation. This we
did in a prospective study with just one antidepressant (the
serotonin norepinephrine reuptake inhibitor (SNRI)
duloxetine), over 6 weeks and with regular and thorough
assessment of sBDNF levels and depression.
The aims of the study were fourfold: (1) to assess changes
in sBDNF levels over a 6-week course of treatment of patients
with MDD; (2) to assess changes in severity of depression
over this same period; (3) to correlate changes in sBDNF with
changes inMDD, and lastly, (4) to predict treatment outcomes
based on a combination of changes in sBDNF and MDD.
We believe the present study may shed more light on the
association between sBDNF andMDD given that (a) only one
antidepressant is used, (b) both BDNF and symptoms of
MDD are assessed more frequently and more thoroughly,
and (c) changes in BDNF and MDD symptoms are combined
to predict treatment outcome.
Our four hypotheses were as follows: (1) following previ-
ous clinical studies of sBDNF concentrations in patients with
MDD (Bocchio-Chiavetto et al. 2010; Sen et al. 2008), base-
line sBDNF levels would be low and related to greater sever-
ity of depression; (2) sBDNF would normalize in parallel to
reduction in depression; that is to say, patients with favorable
treatment outcomes would have higher sBDNF levels at the
end of the study than patients with unfavorable treatment
outcomes; (3) following Tadić et al. (2011) and Dreimüller
et al. (2012), sBDNF concentrations would increase early (i.e.,
in the first 2 weeks of treatment), and this early change would
correlate with early HDRS regression; (4) either baseline
sBDNF concentrations or early change of sBDNF or both
would predict therapeutic outcome.
Method
Sample
An open prospective clinical study was conducted in three
Swiss clinical centers between January 2010 and the end of
2011. Participants were female and male in- and outpatients
suffering from an acute episode of MDD according to the
International Classification of Diseases, 10th edition (ICD-10;
World Health Organization 1994) and who fulfilled the clin-
ical indication criteria for treatment with duloxetine. The
study was carried out according to good clinical practice
principles. The study protocol was approved by local and
hospital ethical committees, and was conducted in accordance
with the ethical standards laid down in the Declaration of
Helsinki. Local committees were regularly informed about
the status and development of the study. All patients gave
written informed consent prior to participation. Severity of
depression was in excess of 17 points on HDRS-17 and more
than 3 points on the Clinical Global Impression (CGI) scale.
Patients had to be free of antidepressants for at least 3 days
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(the elimination time for previous antidepressants). Patients
were excluded from the study if previously treated with a
selective serotonin reuptake inhibitor (SSRI) or venlafaxine,
when there was an indication for another antidepressant than
duloxetine, or when they were known non-responders to
antidepressants. Those with clinically relevant psychiatric
comorbidities or acute suicidality were excluded. Patients
were also excluded if suffering from clinically relevant sys-
temic diseases such as chronic liver or kidney insufficiency,
malignant diseases, severe cardiovascular problems, and in
the case of female patients, if pregnant or planning pregnancy
or if they were breast feeding.
From 31 patients recruited between January 2010 and the
end of 2011, six terminated the study prematurely. Of these,
two declined the treatment and left the hospital following the
baseline visit, one patient was withdrawn from the study due
to non-compliance, and one because of transfer to another
hospital. Two patients terminated the study because of adverse
effects, e.g., moderate to severe insomnia. No serious adverse
events were observed. Baseline characteristics, as well as
blood samples, were collected from all patients included into
the study. For the analyses of results, however, only patients
completing the entire treatment period and with no missing
assessments were considered. Of all those initially recruited,
25 patients fulfilled this requirement; 13 of these were treated
as inpatients and 12 as outpatients. Demographic data for this
sample are summarized in Table 1. Age did not differ between
female (n=8; M=46.4, SD=15.5) and male participants (n=
17; M=42.4, SD=11.2; t(23)=0.73, p=0.47). One patient
suffered from various systemic concomitant diseases. During
the study, 15 patients (60%) were additionally treated with co-
medication, i.e., most commonly with hypnotics (such as
benzodiazepines or zolpidem) or analgesics such as non-
steroid anti-inflammatory drugs (NSAID). Statistical analysis
(i.e., a series of t tests for independent samples, and chi-square
tests) revealed that co-medication did not systematically bias
the results, especially neither BDNF values nor HDRS scores
did differ between patients with co-medication or without.
Furthermore, co-medication was not associated to HDRS≥
50 % response or remission status at week 6.
Procedure
Treatment schedule with duloxetine was uniform in all pa-
tients. The initial dose was 30–60 mg/day (mean=43.2 mg/
day (SD±15.2 mg/day)) which was increased during the first
week to an average dose of 63.6 mg/day (SD±13.2 mg/day)
and by the second week to 69.6 mg/day (SD±18.8 mg/day).
From the second week of treatment to the end of the study
(week 3–6), there were no further dose adjustments. Depres-
sion severity was assessed with the HDRS-17 and CGI at
baseline, and 1, 2, 4 and 6 weeks (±2 days) after the start of
treatment.
Laboratory analysis
For sBDNF sampling, blood (5 ml from antecubital vein) was
collected at baseline, and after 1, 2, and 6 weeks, always at the
same time in the morning. Two probes per sampling were
collected from each patient into Vacutainer tubes (Becton
Dickinson; Allschwil, Switzerland) and the tubes were appro-
priately labeled. After centrifuging (2,000×g, 10 min, 4 °C),
serum was stored in at least two aliquots at −80 °C until assay.
sBDNFwas measured using a BDNFEmax Immunoassay Kit
(Promega; Dübendorf, Switzerland) according to the manu-
facturer’s instructions. Briefly, 96-well microplates (Nunc
MaxiSorpTM, Sigma-Aldrich; Buchs, Switzerland) were coat-
ed with anti-BDNF monoclonal antibody and incubated at
4 °C for 18 h. Then, the plates were incubated in a blocking
buffer for 1 h at room temperature. The samples and BDNF
standards were kept at room temperature (RT) under condi-
tions of horizontal shaking during 2 h, followed by washing
with the appropriate washing buffer. The plates were incubat-
ed with anti-human BDNF polyclonal antibody at RT for 2 h
Table 1 Patients’ characteristics
n=25 Value
Gender Males (%) 17 (68 %)
Females (%) 8 (32 %)
Age years, mean (SD) 43.7 (12.5)
Educational level High school (%) 6 (24 %)
Middle (%) 10 (40 %)
Basic (%) 9 (36 %)
Depressive episode* Mild (%) 1 (4 %)
Moderate (%) 20 (80 %)
Severe (%) 4 (16 %)
Psychotic (%) 0 (0 %)
Recurrant (%) 15 (60 %)
N of prior episodes n (SD) 1.8 (2.0)
Duration of illness years, mean (SD) 8.5 (9.5)
Duration of index episode months, mean (SD) 10.1 (11.7)
Setting inpatients (%)
outpatients (%)
13 (52 %)
12 (48 %)
Pretreatment with AD n (%) 18 (72 %)
Previous response to AD n (%) 17 (68 %)
Mean dosage of duloxetine Visit 1–3, mg (SD) 53.4 (11.5)
Visit 1–5, mg (SD) 65.8 (16.1)
Baseline HDRS score Mean (SD) 22.2 (4.9)
Baseline CGI score Mean (SD) 5.1 (0.61)
Baseline sBDNF, ng/ml Mean (SD) 5.0 (3.6)
AD antidepressant(s); HDRS Hamilton depression rating scale, CGI clin-
ical global impression; sBDNF serum brain-derived neurotrophic factor;
SD standard deviation
*Characterisation of depressive episode according to International Clas-
sification of diseases, 10th edition (ICD-10)
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followed by washing with washing buffer. The plates were
further incubated with an anti-IgY antibody conjugated to
horseradish peroxidase for 1 h at RT, and incubated in perox-
idase substrate and tetramethylbenzidine solution to induce a
color reaction. The reaction was stopped with 1 mol/L hydro-
chloric acid. The absorbance at 450 nm was measured with a
microplate reader (Multiskan AscentTM, Thermo Electron
Corp.). Measurements were performed at least in duplicates.
Specificity of sBDNF analysis (i.e., cross-reactivity to related
neurotrophins) was <3 %, sensitivity was at least 15 pg/ml.
Statistical analysis
Preliminary calculations: Pearson’s correlations were comput-
ed between age, educational level, current and previous illness
history and baseline sBDNF, HDRS, and CGI. Baseline
values of sBDNF levels and HDRS and CGI scores did not
correlate with age, education, duration of illness, duration of
index episode or number of former depressive episodes (all
p values>0.1). Therefore age, education and illness history
were excluded as possible confounders.
Whether gender, setting of treatment, or pretreatment with
another antidepressant had an effect on baseline conditions
were tested using Student’s t tests and Welch (w)-tests. Com-
pared to outpatients, inpatients had higher baseline sBDNF
concentrations (7.56±2.99 vs. 2.24±1.77 ng/ml; w(19.7)=
5.46, p=0.000) and marginally higher HDRS and CGI scores
(HDRS=23.9±5.8 vs. 20.4±2.7,w(17.4)=2.0, p=0.07; CGI=
5.3±0.6 vs. 4.8±0.6; t(23)=2.0, p=0.06).1 Baseline values of
sBDNF, HDRS and CGI did not differ between females and
males (sBDNF=5.11±3.49 vs. 4.96±3.82 ng/ml; t(23)=0.09,
p=0.92; HDRS=22.4±5.2 vs. 22.2±4.8, t(23)=0.09, p=0.93;
CGI=5.4±0.7 vs. 4.9±0.6; t(23)=1.63, p=0.12) or between
those pre-treated with another antidepressant and those not
pre-treated (sBDNF=5.51±3.55 vs. 3.95±3.85 ng/ml; t(23)=
1.00, p=0.33; HDRS=22.2±4.9 vs. 22.3±5.1, t(23)=0.01,
p=1.00; CGI=5.1±0.6 vs.5.0±0.8; t(23)=0.42, p=0.68).
A series of ANOVAs for repeated measures was performed
to calculate changes in HDRS, CGI, and sBDNF values over
four (sBDNF) and five (HDRS and CGI) time points. In case
of deviations from sphericity, statistical tests were performed
using Greenhouse–Geisser corrected degrees of freedom,
though throughout the paper, the original degrees of freedom
are reported with the relevant Greenhouse–Geisser epsilon
value (ε). Single t tests were applied as between post hoc tests,
with Bonferroni-Holm corrections for p values.
Pearson’s correlations were computed for associations be-
tween HDRS, CGI, and sBDNF values.
Changes in HDRS score between different time points
(weeks 1, 2, 4, 6) and baseline were reported as HDRS-
W1delta (and, HDRS-W2delta, HDRS-W4delta, HDRS-
W6delta, respectively).2 Similarly, differences between
sBDNF concentrations at week 1 (or weeks 2 or 6) and
baseline were reported as sBDNF-W1delta (sBDNF-W2delta,
sBDNF-W6delta). Differences from baseline values are re-
ported as changes relative to baseline value.
To examine the extent to which response and remission
were associated with sBDNF levels, cut-off variables were
introduced; as described above, we introduced the factor
responder at three different levels: (1) Early responder after
1 week of treatment, i.e., a decrease in HDRS score of 20% or
more after 1 week of treatment compared to baseline (HDRS≥
20% response at week 1). (2) Early responder after 2 weeks of
treatment, i.e., a decrease in HDRS score of 20% ormore after
2 weeks compared to baseline (HDRS≥20 % response at
week 2). (3) Responder after 6 weeks of treatment, i.e., a
decrease in HDRS score of 50 % or more after 6 weeks of
treatment compared to baseline (HDRS≥50 % response at
week 6).
Next, the cut-off variable remitter was introduced. At the
end of the study, remission was reached if the HDRS score
was 8 points or lower.
To compare HDRS, CGI, and BDNF values between
HDRS≥20 % response at week 1 vs. HDRS≥20 % non-
response at week 1, HDRS≥20 % response at week 2 vs.
HDRS≥20% non-response at week 2, HDRS≥50% response
at week 6 vs. HDRS≥50 % non-response at week 6, and
remitters vs. non-remitters, a series of single t tests was
performed.
Next, to combine patients with high or low sBDNF levels
and further sBDNF change andMDD outcome, sBDNF levels
at the beginning of the study were median-split into patients
with high vs. low BDNF levels. Similarly, sBDNF-W2delta
was median-split to produce groups with “low sBDNF rise”
and “high sBDNF rise.” Then, to calculate further distribu-
tions and odds ratios, a series of chi-square tests was
performed.
Test results with an alpha level below 0.05 are reported as
significant. Effect sizes for t and w tests were calculated
following Cohen (1988), with 0.49≥d≥0.20 indicating small
[S] (i.e., negligible practical importance), 0.79≥d≥0.50 indi-
cating medium [M] (i.e., moderate practical importance), and
d≥0.80 indicating large [L] (i.e., crucial practical importance)
effect sizes. Effect sizes for ANOVAs were indicated with the
partial eta squared (η2), with 0.059≥η2≥0.01 indicating small
1 Nevertheless, inpatients did not differ from outpatients concerning
values of sBDNF levels and HDRS scores at later timepoints and changes
of HDRS scores or sBDNF levels between any timepoint and baseline
were not significantly different between setting groups.
2 Accordingly, when HDRS score was declining over course of treatment,
the value of HDRS-Wxdelta was negative.
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[S], 0.139≥η2≥0.06 indicating medium [M], and η2≥0.14
indicating large [L] effect sizes.
Analyses were conducted using SPSS 20.0 (IBM Compa-
ny, NY, USA) for Windows.
Results
sBDNF concentrations and changes
Descriptive and statistical information for sBDNF concentra-
tions are reported in Table 2. sBDNF concentrations differed
significantly over time. Post hoc comparisons with
Bonferroni-Holm corrections for p values showed that
sBDNF levels increased significantly and continuously from
baseline to week 2. Between week 2 and week 6, sBDNF
levels decreased significantly again; sBDNF levels at baseline
and week 6 did not differ significantly.
Change of depressive symptoms
Descriptive and statistical analyses of the HDRS and CGI
values over time are summarized in Table 2. HDRS scores
decreased significantly over time. Post hoc comparisons with
Bonferroni-Holm corrections for p values revealed that de-
crease in HDRS score was significant after 1 week of treat-
ment and continued to decrease significantly till week 4, while
HDRS scores at weeks 4 and 6 did not differ statistically
significantly. CGI scores decreased significantly over time
(Table 2). Post hoc comparisons with Bonferroni-Holm cor-
rections for p values revealed that CGI regression was also
significant as early as week 1, decreased almost steadily
thereafter, and was still decreasing between weeks 4 and 6.
Association between sBDNF levels and HDRS scores, early
improvement, response, and remission
A higher baseline sBDNF level was associated with a higher
baseline HDRS score (r=0.45, p=0.024).3 There were no
significant correlations between HDRS score and sBDNF
values at weeks 1, 2, or the end of treatment (r’s<0.1, p’s>
0.2). sBDNF levels did not differ between favorable and
unfavorable treatment course at any time (i.e., sBDNF-W1/
HDRS≥20 % response at week 1 vs. HDRS≥20 % non-
response at week 1, sBDNF-W2/HDRS≥20 % response at
week 2 vs. HDRS≥20 % non-response at week 2, sBDNF-
W6/HDRS≥50 % response at week 6 vs. HDRS≥50 % non-
response at week 6, and sBDNF-W6/remission vs. non- re-
mission) (t tests: all p’s>0.2).
Baseline sBDNF and sBDNF level changes after the first
2 weeks of treatment and treatment course
As Table 3 shows, baseline sBDNF concentrations were
higher in patients with HDRS≥20 % response at week 2 than
with HDRS≥20 % non-response at week 2 (descriptively, p=
0.065, d=1.06 [L]), and baseline sBDNF levels were signifi-
cantly higher in HDRS≥50 % response at week 6 than in
HDRS≥50 % non-response at week 6 (p=0.024, d=1.15 [L];
Fig. 1). The “remission” and “non-remission” groups did not
differ significantly in baseline sBDNF (p>0.1, d<0.22 [S]).
As regards to change in sBDNF concentrations over time,
sBDNF-W1delta and sBDNF-W2delta were descriptively
higher in patients with HDRS≥50 % non-response at
week 6 than patients with HDRS≥50 % response at
week 6 (p=0.102, d=1.03[L] and p=0.146, d=0.81[L],
resp., Fig. 1). Further, a higher sBDNF-W2delta, i.e., a
significant rise in sBDNF levels over the first 2 weeks of
treatment, was associated with a smaller HDRS-W2delta,
i.e., a smaller decline in HDRS scores over 2 weeks (r=
0.48; p=0.018). Finally, the more the absolute sBDNF-
W1delta and the percentage of sBDNF-W1delta were
higher, the lower the baseline sBDNF level (r=−0.42,
p=0.036; r=−0.46, p=0.020, respectively).
Prediction of treatment outcome as a function of baseline
sBDNF, early sBDNF changes, and HDRS≥20 % response
at weeks 1 or 2
To investigate the predictive value of baseline sBDNF levels,
early sBDNF rise, and a combination of both, for treatment
outcome, χ2 tests were performed, as presented in Table 4.
Patients with “high baseline sBDNF” or with “high baseline
sBDNF” and “low sBDNF-W2delta” were more likely to be
final responders (HDRS≥50 % response at week 6) than
patients with “low baseline sBDNF” or with “low base-
line sBDNF” and “high sBDNF-W2delta”. 60 % of pa-
tients with “low baseline sBDNF” and “high sBDNF-
W2delta”had a HDRS≥50 % non-response at week 6,
while 90 % of patients of fulfilling the criteria had a
HDRS≥50 % response at week 6. To evaluate the pre-
dictive value of sBDNF variables, we also analyzed the
association of HDRS≥20 % response at weeks 1 and 2
with treatment outcome. HDRS≥20 % response at week
2 marginally predicted HDRS≥50 % response at week 6
(χ2(n=25, df=1)=3.18, p=0.08; Table 4). HDRS≥20 %
response at week 2 rather than baseline HDRS scores
(Table 3) were associated with treatment outcome.
To summarize, a high baseline sBDNF and a low sBDNF
rise at the beginning of treatment were associated with favor-
able treatment outcome, even if the baseline HDRS score was
high.
3 After including all initially recruited patients (n=31) into the analysis,
correlation between baseline values of sBDNF and HDRS was similar
(r=0.463; p=0.010).
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Table 2 Hamilton depression rating scores (HDRS) and clinical global impression scores (CGI) and brain-derived neurotrophic factor serum
concentrations (sBDNF) at baseline and over 6 weeks of treatment
Mean (±SD) ANOVA Post hoc comparisons (p)
Baseline vs. Week 1 vs. Week 2 vs. Week 4 vs.
HDRS, score Baseline: 22.2 (±4.9)
Week 1: 16.9 (±7.6)
Week 2: 13.8 (±7.5)
Week 4: 9.0 (±6.6)
Week 6: 7.5 (±5.6)
F(4, 92)=45.37
p=0.000
η2=0.664 [L]
ε=0.67
Week 1: 0.001
Week 2: <0.0001
Week 4: <0.0001
Week 6: <0.0001
week 2: 0.047
Week 4: <0.0001
Week 6: <0.0001
Week 4: 0.005
Week 6: 0.001
Week 6: n.s.
CGI, score Baseline: 5.1 (±0.61)
Week 1: 4.5 (±0.83)
Week 2: 4.0 (±1.00)
Week 4: 3.5 (±1.14)
Week 6: 2.8 (±1.25)
F(4, 92)=39.28
p=0.000
η2=0.631 [L]
ε=0.67
Week 1: 0.001
Week 2: <0.0001
Week 4: <0.0001
Week 6: <0.0001
Week 2: 0.049
Week 4: <0.0001
Week 6: <0.0001
Week 4: n.s.
Week 6: <0.0001
Week 6: 0.009
sBDNF, ng/ml Baseline: 5.01 (±3.64)
Week 1: 8.66 (±5.93)
Week 2: 11.03 (±8.00)
Week 4:—
Week 6: 5.99 (±3.66)
F(3, 72)=7.97
p=0.001
η2=0.249 [L]
ε=0.76
Week 1: 0.056
Week 2: 0.009
Week 6: n.s.
Week 2: n.s.
Week 6: n.s.
Week 6: 0.016 –
n.s. p>0.05; [L] large effect size
Table 3 Baseline values and early changes in HDRS scores and sBDNF concentrations in patients with (non-)response after 2 or 6 weeks, or with (non-)
remission after 6 weeks
HDRS≥20 % response at week 2 (n=20)
vs.
HDRS≥20 % non-response at week 2
(n=5)
HDRS≥50 % response at week 6 (n=18)
vs.
HDRS≥50 % non-response at week 6
(n=7)
Remission (n=16)
vs.
non-remission (n=9)
Baseline sBDNF ng/ml 5.68±3.59 t(23)=1.94, p=0.065 6.00±3.57 t(23)=2.41, p=0.024 5.33±3.09 t(23)=0.58, p=0.567
2.33±2.67 d=1.06 [L] 2.44±2.51 d=1.15 [L] 4.43±4.62 d=0.22 [S]
sBDNF-W1delta ng/ml 3.26±6.96 t(23)=0.60, p=0.553 1.77±3.37 t(6.55)=1.77, p=0.123 1.83±3.57 t(23)=1.99, p=0.058
5.23±4.04 d=0.35 [S] 8.49±9.83 d=0.91 [L] 6.88±9.10 d=0.73 [M]
sBDNF-W1delta (%) 134±310 t(4.12)=1.34, p=0.250 63±103 t(6.04)=1.93, p=0.102 70±108 t(8.10)=1.77, p=0.114
894±1263 d=0.83 [L] 859±1091 d=1.03 [L] 671±1016 d=0.83 [L]
sBDNF-W2delta ng/ml 6.57±9.00 t(23)=0.37, p=0.718 5.15±7.91 t(23)=1.11, p=0.279 5.13±8.32 t(23)=.93, p=0.362
5.06±3.12 d=0.22 [S] 9.15±8.61 d=0.48 [S] 8.29±7.84 d=0.39 [S]
sBDNF-W2delta (%) 265±517 t(23)=1.47, p=0.156 193±479 t(7.26)=1.63, p=0.146 212±506 t(23)=1.52, p=0.142
749±1111 d=0.56 [M] 797±934 d=0.81 [L] 629±874 d=0.58 [M]
Baseline HDRS score 22.3±5.1 t(23)=0.12, p=0.905 23.2±4.9 t(23)=1.69, p=0.106 22.4±4.2 t(23)=0.18, p=0.857
22.0±4.1 d=0.06 19.7±4.0 d=0.78 [M] 22.0±6.1 d=0.08
HDRS-W1delta score −6.6±5.6 t(23)=2.01, p=0.056 −6.2±1.5 t(23.00)=2.26, p=0.034 −6.3±5.8 t(23)=0.98, p=0.336
−1.2±3.3 d=1.17 [L] −2.3±0.9 d=3.15 [L] −4.0±5.3 d=0.41 [S]
HDRS-W1delta (%) −30.6±26.6 t(23)=1.98, p=0.060 −29.7±29.5 t(23)=1.23, p=0.228 −29.4±29.0 t(23)=0.92, p=0.366
−5.7±17.2 d=1.11 [L] −15.2±14.4 d=0.62 [M] −19.1±21.9 d=0.40 [S]
HDRS-W2delta score −10.7±5.3 t(15.17)=6.86, p=0.000 −10.4±6.6 t(22)=2.55, p=0.018 −10.4±6.9 t(22)=2.01, p=0.057
0.4±2.4 d=2.70 [L] −3.6±3.9 d=1.25 [L] −5.1±4.9 d=0.89 [L]
HDRS-W2delta (%) −49.4±23.8 t(22)=4.70, p=0.000 −46.1±30.8 t(22)=2.01, p=0.057 −47.3±32.1 t(22)=1.91, p=0.070
2.8±11.9 d=2.77 [L] −20.2±22.8 d=0.96 [L] −24.0±22.7 d=0.84 [L]
Absolute values and relative changes of HDRS and sBDNF concentrations are reported by mean and range of standard deviation (±SD). Group
differences are tested by t tests for statistical significance. Effect sizes d are reported. [L] large effect size, i.e., d≥0.80; [M]medium effect size, i.e., 0.79≥
d≥0.50; [S] small effect size, i.e., 0.49≥d≥0.20;remission HDRS score ≤7 after 6 weeks; HDRS-W1delta HDRS change between week 1 and baseline;
HDRS-W2delta HDRS change between week 2 and baseline; sBDNF-W1delta sBDNF level change between week 1 and baseline; sBDNF-W2delta
sBDNF level change between week 2 and baseline
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Discussion
The key findings of the present study are that in a sample of
patients suffering from major depressive disorders, a higher
baseline level of sBDNF concentration, along with an early
improvement to treatment predicted successful treatment out-
come after 6 weeks. However, an initial increase in sBDNF
concentrations during treatment was not associated with
successful treatment outcome. Further, treatment remission
was not associated with sBDNF levels.
We now consider in turn our four hypotheses. First, on the
basis of previous clinical studies (cf. Bocchio-Chiavetto et al.
2010; Brunoni et al. 2008; Sen et al. 2008), we expected that
low baseline sBDNF concentrations would be associated with
more severe depression. This hypothesis was not supported.
Instead, patients with initially high sBDNF levels were also
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Fig. 1 Courses of sBDNF
concentrations in the group of
patients with HDRS≥50 %
response at week 6 vs. the group
of patients with HDRS≥50 %
non-response at week 6;
(*p<0.05)
Table 4 Prediction of therapy outcome (i.e., HDRS≥50 % response or remission after 6 weeks) as a function of high baseline sBDNF concentrations,
low sBDNF level rises by 2 weeks, early HDRS≥20 % response after 1 week and after 2 weeks, respectively, or by a combination of these conditions
HDRS≥50 % response at week 6
(n=18/25, 72.0 %)
Remission
(n=16/25, 64.0 %)
ppv χ2 Test
OR (CI)
ppv χ2 Test
OR (CI)
High baseline sBDNF
(n=13/25, 52.0 %)
12/13 χ2 (n=25, df=1)=5.54, p=0.02 10/13 χ2 (n=25, df=1)=1.96, p=0.16
92.3 % 12.0 (1.2–123.7) 76.9 % 3.3 (0.6–18.5)
Low sBDNF W2delta
(n=12/25, 48.0 %)
11/12 χ2 (n=25, df=1)=4.43, p=.04 9/12 χ2 (n=25, df=1)=1.21, p=.27
91.7 % 9.4 (0.9–95.9) 75.0 % 2.6 (0.5–14.1)
High baseline sBDNF and low sBDNF
W2delta (n=10/25, 40.0 %)
9/10 χ2 (n=20, df=1)=5.50, p=0.02 7/10 χ2 (n=20, df=1)=1.82, p=0.18
90.0 % 13.5 (1.2–152.2) 70.0 % 3.5 (0.5–22.3)
HDRS≥20 % response at week 1
(n=13/25, 52.0 %)
11/13 χ2 (n=25, Df=1)=2.13, p=0.14 10/13 χ2 (n=25, Df=1)=1.96, p=0.16
84.6 % 3.9 (0.6–26.1) 76.9 % 3.3 (0.6–18.5)
HDRS≥20 % response at week 2
(n=20/25, 80.0 %)
16/20 χ2 (n=25, df=1)=3.18, p=0.08 14/20 χ2 (n=25, df=1)=1.56, p=0.21
80.0 % 6.0 (0.7–48.9) 70.0 % 3.5 (0.5–26.6)
High baseline sBDNF and HDRS≥20 %
response at week 2 (n=12/25, 48.0 %)
11/12 χ2 (n=16, df=1)=7.11, p=0.01 9/12 χ2 (n=16, df=1)=3.20, p=0.07
91.7 % 33.0 (1.6–698.0) 75.0 % 9.0 (0.7–122.8)
High baseline sBDNF and low sBDNF
W2delta and HDRS≥20 % response at
week 2 (n=9/25, 36.0 %)
8/9 χ2 (n=13, df=1)=5.31, p=0.02 6/9 χ2 (n=13, df=1)=1.94, p=0.16
88.9 % 24.0 (1.1–518.6) 66.7 % 6.0 (0.4–85.2)
High baseline sBDNF sBDNF≥3.5 ng/ml; low sBDNF W2delta sBDNF W2delta≤70 %; ppv positive predictive value, i.e., the probability rate of a
positive treatment outcome (HDRS≥50 % response at week 6 or remission) in patients fulfilling a precondition as listed in column 1; e.g., 92.3 % of
patients with high baseline sBDNF reached the condition of HDRS≥50 % response at week 6
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those with highest remission and response rates. These results
are at odds with the negative association between severity of
untreated depression and sBDNF levels reported by others
(Gervasoni et al. 2005; Gonul et al. 2005; Karege et al. 2002;
Shimizu et al. 2003; Yoshimura et al. 2007). We found the
opposite correlation between baseline values of HDRS and
sBDNF; i.e., more severe depression was linked with higher
baseline sBDNF levels. In the absence of any clues in the
current literature as to why our pattern of results does not
match previous findings, we offer the following speculations.
First, though the patient sample was heterogenous concerning
age, gender, educational level, and variables of illness history,
appropriate statistical procedures rigorously excluded possible
confounding effects. Second, in a previous study (Giese et al.
2013), we found that quality of sleep as well as tobacco
consumption alter sBDNF levels, and perhaps these con-
founders should have been more thoroughly controlled before
the beginning of treatment. Next, further possible BDNF
confounders, which we did not control for, are body weight,
platelet count, health-related life style, daily exercise level,
drinking habits, and hormonal status in fertile women
(Berchtold et al. 2001; Bus et al. 2011; Chan et al. 2008;
Lommatzsch et al. 2005; Pluchino et al. 2013; Schmidt-
Kassow et al. 2012; Tang et al. 2008; Vanevski and Xu
2013; Ziegenhorn et al. 2007). Finally, in animal studies,
Larsen et al. (2010) showed that chronic unpredictable stress
also induced a rise in sBDNF. Therefore, though highly spec-
ulative, we consider, that higher sBDNF levels in patients with
more severe depression before treatment may reflect more
pronounced unspecific stress responses, which could reflect
a compensatory mechanism.
Our second hypothesis was that there would be a gradual
increase in sBDNF levels towards normal in parallel to ame-
lioration of depression, resulting in higher sBDNF levels in
patients with response or remission than in patients with
unfavorable treatment outcome. The hypothesis was not sup-
ported. Although HDRS scores (and CGI scores) decreased
steadily towards normality, an initial sBDNF increase between
baseline and week 2 was not stable but fell back to baseline
levels. This seems to be in line with some previous studies.
Though some clinical studies on sBDNF in MDD show a
trend to normalization (Aydemir et al. 2006; Gonul et al.
2005), others do not (Deuschle et al. 2013; Matrisciano et al.
2009). While in previous studies, patient samples were treated
with a variety of different antidepressant agents (Gervasoni
et al. 2005; Gonul et al. 2005; Tadić et al. 2011), and therefore
differential effects might have been missed, this study was
restricted to the effect of duloxetine. In animal studies (Larsen
et al. 2007, 2008) as well as in clinical comparative studies
(Başterzi et al. 2009; Deuschle et al. 2013; Hellweg et al.
2008; Matrisciano et al. 2009), it has been shown that the
degree and temporal course of BDNF changes depend on the
antidepressant used, and sBDNF level increases under
antidepressant treatment are less likely with serotonin norepi-
nephrine reuptake inhibitor (SNRI) than with SSRI (Başterzi
et al. 2009; Matrisciano et al. 2009). Therefore, as our data
indicate, and in line with other studies on SNRI, HDRS
response or remission under duloxetine treatment seems not
to be causally linked to normalization of a low baseline
sBDNF. Results from a study using one antidepressant do
not necessarily extend to treatment schedules with other
agents.
Our third hypothesis, following Tadić et al. (2011), was that
there would be changes in sBDNF levels during the early
course of treatment and that an early increase in sBDNF
concentrations would co-occur with a simultaneous decrease
in HDRS score. We found, as did Tadić et al. (2011), an
increase in BDNF serum levels in the first 2 weeks of treat-
ment, accompanied by a regression in HDRS score. However,
contrary to expectation, degree of early sBDNF increase
(sBDNF-deltaW2) correlated negatively with degree of
HDRS score regression; i.e., the more HDRS decreased over
the first 2 weeks of treatment, the less sBDNF concentrations
increased. Therefore, it seems that the acute early rise in
sBDNF is associated with more acute or severe pathology
rather than with favorable early treatment outcomes. This
would be in line with the observation that stress induces rise
of sBDNF (Larsen et al. 2010). Remarkably, Gervasoni et al.
(2005) also found that increases in sBDNF levels were linked
to more severe depression. Therefore, our results are partly in
line with existing literature, supporting the idea that a pro-
nounced sBDNF increase is associated with more severe
pathology.
The dynamics of sBDNF changes under antidepressant
treatment are complex. The early sBDNF rise seems to reflect
rapid posttranscriptional mechanisms (Jacobsen and Mørk
2004; Musazzi et al. 2009), while the increase in BDNF-
RNA-expression occurs later and depends on the antidepres-
sant employed (De Foubert et al. 2004; Khundakar and
Zetterström 2006; Larsen et al. 2008). Further, the early
sBDNF increase could also be associated with an agonist-
stimulated release of BDNF from platelets, the main BDNF
pool in blood, the extent of which varies according to the
antidepressant administered (Watanabe et al. 2010). Finally,
the discrepancy between sBDNF increase and psychopatho-
logical improvement may also be explained by a rapid and
saturable mechanism of blood–brain-barrier transfer, which
may be subject to as yet unknown regulating factors (Pan et al.
1998).
To summarize, the temporal changes in sBDNF under
antidepressant treatment for MDD are subject to numerous
kinetic influences and vary with the particular antidepressant
employed.
While this study using duloxetine demonstrated an early
though transient sBDNF rise, studies with other antidepres-
sants have not reported sBDNF levels during the first 2 weeks,
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and may have missed an early but transient sBDNF change
(e.g., Başterzi et al. 2009; Deuschle et al. 2013; Hellweg et al.
2008; Matrisciano et al. 2009).
Again, as with sBDNF level changes following 6 weeks of
treatment, changes early in treatment did not correspond to
changes in HDRS scores. Though the early rise in sBDNF
during treatment seems to be a robust phenomenon in our
study, it is not necessarily linked in any causal fashion to the
early antidepressant effect of duloxetine. Instead, it seems that
this early increase in sBDNF reflects an early reaction to the
start of therapy with a drug, independent to its subsequent
efficacy.
Our fourth hypothesis was that baseline sBDNF and early
change in sBDNF, along with early HDRS≥20 % response,
would predict therapeutic outcome, i.e., therapy response or
remission. Results support the hypothesis in that we found
significantly higher baseline sBDNF concentrations in re-
sponse patients than in non-response patients, with large effect
sizes. Additionally, high baseline sBDNF levels were predic-
tive to response, while low baseline sBDNFwere predictive to
non-response. We conclude, therefore, that baseline sBDNF is
an indicator of individual resources for recovery from depres-
sion rather than an indicator of actual baseline severity.
Concerning BDNF changes, we found a pattern in which a
greater rise in sBDNF levels during the first 2 weeks was
associated with an unfavorably low baseline sBDNF, and with
later non-response. This pattern supports the impression that
the early sBDNF rise at the beginning of duloxetine treatment
maybe a stress-associated phenomenon which is linked to
more severe pathology and proneness to depression rather
than to a favorable course of illness. Indeed, and contrary to
expectations, a greater early rise in sBDNF is a negative
prognostic indicator for response to duloxetine treatment.
In line with Stassen et al. (1996) and Tadić et al. (2011), we
replicated the finding that HDRS≥20 % response in the first
2 weeks of treatment was a positive predictive marker for
HDRS≥50% response after 6 weeks of treatment. This result,
in such a small sample, further supports the robustness of the
results and conclusions of Stassen et al.’s studies (Stassen
et al. 1993, 1996, 1997).
In addition, we were able to show that baseline sBDNF
concentrations have a similar and indeed better predictive
power with respect to treatment effects than “HDRS≥20 %
response at week 2.”While it is obvious that a serum marker,
which is derived before treatment commences, is of more
value to clinical practice than observation of the course of
treatment over 2 weeks, our results show a combination of
both variables (“baseline sBDNF” and “HDRS≥20 % re-
sponse at week 2”) improves prediction.
Various limitations of this study require mention. First, due
to the open design of the study, none of the possible study
biases can be excluded. The statistical analysis indicates some
highly significant changes, and is based on multiple analyses
of a small sample; therefore, the pattern of results should be
interpreted with caution. Nevertheless, though this pilot study
sample was small and lacked sufficient power to examine
detailed associations between HDRS score and BDNF level
changes, it is remarkable that effect sizes for differences
between responders and non-responders were so large
(Cohen 1988). We also note that effect size calculations are
independent from sample sizes. Additionally, these results
justify further well-designed studies with larger sample sizes.
We also acknowledge that the small sample size and lack of
control group might be an issue from the point of view of
statistics. Accordingly, again, caution is warranted in
interpreting the present pattern of results.
Further, though epidemiologically major depression is
more common in women than in men, in the present sample,
men were overrepresented. Therefore, this naturalistic sample
is not representative for other clinical samples.
Another limitation of this study is that the influence of
unassessed factors like body weight or smoking cannot be
excluded. Additionally, we could not take into account status
of functionally relevant BDNF-gene-polymorphisms like the
val66met polymorphism: meta-analyses show that heterozy-
gotes are more likely to respond to antidepressant treatment
than homozygotes (Kocabas et al. 2011; Zou et al. 2010).
The antidepressant selected for the treatment was
duloxetine, a dual-acting drug, characterized by a balanced
increase of both noradrenaline and serotonin concentrations in
the brain (Bymaster et al. 2001). While the strength of this
study is that patients received a uniform antidepressant treat-
ment, our results cannot be generalized to treatments with
other antidepressants. Further, in lack of a control group, we
could not proof the specificity of sBDNF-level changes under
duloxetine treatment in comparison to treatment with other
antidepressants.
Finally, although sBDNF levels after 6 weeks did not differ
from baseline sBDNF levels, it remains possible that sBDNF
would have normalized with longer treatment; in a small study
of various antidepressants,Matrisciano et al. (2009) found that
BDNF did not increase after 5 weeks of treatment with
venlafaxine but did after 6 months.
In conclusion, this open, prospective multi-center study of
25 patients with moderate major depression revealed low
sBDNF is not necessarily associated with more severe depres-
sion. Early sBDNF rise is not linked to a positive treatment
outcome. The combination of high baseline sBDNF, low early
sBDNF rise, and early HDRS response predicted overall
treatment response. Further, larger and controlled studies are
necessary to confirm these clinically relevant results.
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